Seagen company information, Employees & Contact Information

Seagen Announces Plans to Expand Pacific Northwest Biomanufacturing Capacity to Support Growing Portfolio of Transformative Cancer Medicines Business Wire

Seattle Genetics shortens name to Seagen, dropping local connection as it goes global Fierce Pharma

Astellas and Seagen Announce Positive Topline Results For PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) as First-Line Treatment for Advanced Urothelial Cancer PR Newswire

Seattle Genetics? Not anymore. The biotech has shortened its name to Seagen to illustrate global expansion Endpoints News

Seagen and Zai Lab Announce Regional Strategic GlobeNewswire

Seagen Second Quarter 2023 Financial Results Demonstrate Exceptional Commercial Performance Driving Record Product Sales with Strong Growth and Momentum Stock Titan

Pfizer buys Bothell-based Seagen for $43B, boosts access to cancer drugs The Seattle Times

Seattle Genetics adopts new name, sheds local branding The Business Journals

Seagen President, CEO And Chairman Clay Siegall Takes Leave Of Absence citybiz

Real-world patient characteristics, treatment patterns, and clinical outcomes associated with tucatinib therapy in HER2-positive metastatic breast cancer Frontiers

Seagen Third Quarter 2023 Financial Results Reflect Strong Product Sales Growth, and Significant Portfolio and Pipeline Progress Business Wire

Seagen Announces Resignation of President, Chairman & CEO Clay Siegall Stock Titan

European Commission Approves PADCEV™ (enfortumab vedotin) for Locally Advanced or Metastatic Urothelial Cancer PR Newswire

Seagen and LAVA Therapeutics Announce Exclusive Worldwide GlobeNewswire

Pfizer Invests $43 Billion to Battle Cancer Business Wire

Seagen Stockholders Approve Acquisition by Pfizer Business Wire

Seagen Reports First Quarter 2023 Financial Results Business Wire

Seagen Reports Fourth Quarter and Full Year 2022 Financial Results Business Wire

Seagen and Genmab Announce FDA Accelerated Approval for TIVDAK (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer Business Wire

Seagen Appoints Lee Heeson as Executive Vice President, Commercial International Business Wire

FDA grants priority review to Tukysa regimen for advanced colorectal cancer Healio

ADCs as biological missiles for targeted therapies Pharmaceutical Technology

FDA Grants Priority Review to sBLA for Enfortumab Vedotin Plus Pembrolizumab in Advanced Urothelial Cancer OncLive

Nonfucosylation of an anti-TIGIT antibody enhances FcγR engagement, driving innate immune activation and antitumor activity Frontiers

FDA Grants Accelerated Approval for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer PR Newswire

Alternative Approach to the Large-Scale Synthesis of the Densely Functionalized Pyrrolidone BMT-415200 ACS Publications

Orthogonal Cysteine Protection Enables Homogeneous Multi-Drug Antibody–Drug Conjugates Wiley Online Library

Development of orally active inhibitors of protein and cellular fucosylation PNAS

Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-Line Advanced Bladder Cancer PR Newswire

Seattle Genetics Announces U.S. FDA Approval of TUKYSA™ (tucatinib) for People with Advanced Unresectable or Metastatic HER2-Positive Breast Cancer Business Wire

U.S. FDA Grants Regular Approval and Expands Indication for PADCEV® (enfortumab vedotin-ejfv) for Patients with Locally Advanced or Metastatic Urothelial Cancer PR Newswire

Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab ASCO Publications

MOUNTAINEER and DESTINY-CRC01 Trials Expand Second-Line Options for HER2+ mCRC OncLive

Orthogonal Cysteine Protection Enables Homogeneous Multi-Drug Antibody–Drug Conjugates Wiley Online Library

Seagen to Host Conference Call and Webcast Discussion of First Quarter 2021 Financial Results on April 29, 2021 FinancialContent

Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results ScienceDirect.com

Seagen to Host Conference Call and Webcast Discussion of Second Quarter 2022 Financial Results on July 28, 2022 FinancialContent

Seagen and Astellas Announce U.S. FDA Acceptance of Two Supplemental Biologics License Applications for PADCEV® (enfortumab vedotin-ejfv) in Locally Advanced or Metastatic Urothelial Cancer | Daily Penny Alerts FinancialContent

Seagen Canada Announces Availability of PADCEV® to Treat Advanced Bladder Cancer PR Newswire Canada

Run Rules with Autocorrelated Data for Continued Process Verification BioProcess International

Seagen (SGEN) Stock Price, News & Analysis MarketBeat

Update on Novel Treatments for Peripheral T-cell Lymphoma The ASCO Post

TUKYSA® (tucatinib) Reimbursed in Ontario, Manitoba and Saskatchewan for the Treatment of Patients with Advanced or Metastatic HER2-Positive Breast Cancer PR Newswire Canada

TUKYSA® (tucatinib) Reimbursed in Quebec for the Treatment of Patients with Advanced or Metastatic HER2-Positive Breast Cancer PR Newswire Canada

PADCEV™ (enfortumab vedotin) treatment for Locally Advanced or Metastatic Urothelial Cancer receives market authorisation in Singapore Media OutReach Newswire

SeaGen tidal power marine turbine plugs into electricity grid The Guardian